Agios Pharmaceuticals AGIO
$27.60 −$1.16 (-4.03%)
Market closed · Nov 20, 8:10 pm ET · Last extended-hours $27.60 0.00%
Open$28.01
Prev close$28.76
Day range$27.43 – $29.14
Volume776.2K
Market cap$1.65B
P/E (TTM)–
Dividend yield–
Fundamentals
Latest reported quarter: Q3, ended Sep 2026
Revenue$55.39M+330.0% YoY
Operating profit-$77.16M+34.0% YoY
Net profit-$65.05M+37.1% YoY
Diluted EPS-$1.09+38.8% YoY
Free cash flow-$60.42M+32.6% YoY
Operating cash flow-$59.24M
Revenue, last 8 quarters
Net profit, last 8 quarters
Diluted EPS by quarter
Free cash flow by quarter
Annual revenue
Profitability & balance sheet
Gross margin93.8%
Operating margin-297.7%
Net margin-264.8%
Return on equity-32.9%
Return on assets-30.4%
Return on invested capital-35.5%
Current ratio9.69
Liabilities / assets8.0%
Cash & investments$630.01M
Total debt$6.88M
Net cash (debt)$623.13M
Income statement
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Revenue as Reported | $55.39M | $44.75M | $20.75M | $54.03M | $19.97M |
| Total Operating Revenue | $55.39M | $44.75M | $20.75M | $54.03M | $19.97M |
| Cost of Revenue | $2.53M | $3.00M | $1.32M | $6.35M | $1.88M |
| Gross Profit | $52.86M | $41.75M | $19.43M | $47.68M | $18.09M |
| Operating Expense | $130.02M | $152.30M | $129.45M | $519.82M | $139.67M |
| Selling and Admin Expenses | $56.53M | $51.55M | $48.30M | $180.28M | $51.61M |
| Research & Development | $73.49M | $100.75M | $81.15M | $339.54M | $88.06M |
| Operating Profit | -$77.16M | -$110.55M | -$110.03M | -$472.13M | -$121.58M |
| Net Non-Operating Interest Income (Expense) | $8.88M | $9.73M | $10.80M | $56.38M | $12.41M |
| Non-Operating Interest Income | $8.88M | $9.73M | $10.80M | $56.38M | $12.41M |
| Other Income (Expense) | $3.24M | $119,000.00 | $119,000.00 | $1.96M | $113,000.00 |
| Special Income (Charges) | $2.97M | – | – | $0.00 | $0.00 |
| -Gain on Sale Of Business | $2.97M | – | – | $0.00 | $0.00 |
| Other Non-Operating Income (Expenses) | $266,000.00 | $119,000.00 | $119,000.00 | $1.96M | $113,000.00 |
| Pretax Profit | -$65.05M | -$100.70M | -$99.11M | -$413.80M | -$109.06M |
| Net Profit | -$65.05M | -$100.70M | -$99.11M | -$412.78M | -$108.04M |
| Profit from Continuing Operations | -$65.05M | -$100.70M | -$99.11M | -$412.78M | -$108.04M |
| Net Income to Parent Company | -$65.05M | -$100.70M | -$99.11M | -$412.78M | -$108.04M |
| Net Income to Common Stockholders | -$65.05M | -$100.70M | -$99.11M | -$412.78M | -$108.04M |
| Basic EPS | -$1.09 | -$1.69 | -$1.69 | -$7.12 | -$1.85 |
| Diluted EPS | -$1.09 | -$1.69 | -$1.69 | -$7.12 | -$1.85 |
| Tax | – | – | – | -$1.02M | -$1.02M |
Balance sheet
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Total Assets | $1.06B | $1.11B | $1.18B | $1.30B | $1.30B |
| Total Current Assets | $752.10M | $717.67M | $834.84M | $942.05M | $942.05M |
| Cash and Cash Equivalents & Short-Term Investments | $630.01M | $617.58M | $113.60M | $854.43M | $854.43M |
| -Cash and Cash Equivalents | $128.55M | $99.65M | $113.60M | $89.13M | $89.13M |
| -Short Term Investments | $501.46M | $517.93M | – | $765.30M | $765.30M |
| Receivables | $32.90M | $24.22M | – | $10.58M | $10.58M |
| -Accounts Receivable | $25.25M | $20.11M | $16.13M | $10.58M | $10.58M |
| -Other Receivables | $7.64M | $4.10M | – | – | – |
| Inventory | $37.84M | $30.15M | $35.09M | $32.92M | $32.92M |
| Other Current Assets | $51.35M | $45.72M | $799.76M | $44.13M | $44.13M |
| Total Non-Current Assets | $311.94M | $390.76M | $350.15M | $355.17M | $355.17M |
| Net PPE | $30.85M | $33.82M | – | $41.23M | $41.23M |
| -Gross PPE | $30.85M | $33.82M | – | $101.34M | $101.34M |
| Investments and Advances | $277.01M | $347.25M | – | $310.01M | $310.01M |
| -Available for Sale Securities | $277.01M | $347.25M | – | $310.01M | $310.01M |
| Other Non-Current Assets | $4.08M | $9.68M | $350.15M | $3.93M | $3.93M |
| Total Liabilities | $84.70M | $82.40M | $75.88M | $104.11M | $104.11M |
| Total Current Liabilities | $77.59M | $70.22M | $58.85M | $82.21M | $82.21M |
| Payables | $19.93M | $16.35M | – | $18.36M | $18.36M |
| -Accounts Payable | $19.93M | $16.35M | $13.75M | $18.36M | $18.36M |
| Current Accrued Expenses | $18.93M | $19.90M | $14.61M | $18.20M | $18.20M |
| Short-Term Debt and Capital Lease Obligation | $19.65M | $19.23M | – | $18.39M | $18.39M |
| -Current Capital Lease Obligation | $19.65M | $19.23M | $18.81M | $18.39M | $18.39M |
| Total Non-Current Liabilities | $7.12M | $12.19M | $17.03M | $21.91M | $21.91M |
| Long Term Debt and Capital Lease Obligation | $6.88M | $11.95M | $16.94M | $21.82M | $21.82M |
| -Long Term Capital Lease Obligation | $6.88M | $11.95M | $16.94M | $21.82M | $21.82M |
| Other Non-Current Liabilities | $240,000.00 | $240,000.00 | $17.03M | $90,000.00 | $90,000.00 |
| Total Equity | $979.34M | $1.03B | $1.11B | $1.19B | $1.19B |
| Stockholders' Equity | $979.34M | $1.03B | $2.43B | $1.19B | $1.19B |
| Capital Stock | $76,000.00 | $76,000.00 | $0.00 | $75,000.00 | $75,000.00 |
| -Common Stock | $76,000.00 | $76,000.00 | – | $75,000.00 | $75,000.00 |
| -Preferred Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Additional Paid-In Capital | $2.61B | $2.59B | $2.57B | $2.56B | $2.56B |
| Retained Earnings | -$826.56M | -$761.52M | -$802.49M | -$561.71M | -$561.71M |
| Less: Treasury Stock | -$802.49M | -$802.49M | -$660.82M | -$802.49M | -$802.49M |
| Gains/Losses Not Affecting Retained Earnings | -$4.29M | -$1.80M | – | $2.19M | $2.19M |
| -Accumulated Depreciation | – | – | – | -$60.12M | -$60.12M |
| -Total Tax Payable | – | – | – | $0.00 | $0.00 |
Cash flow
| Line item | 2026 Q3 | 2026 Q2 | 2026 Q1 | 2025 ANNUAL | 2025 Q4 |
|---|---|---|---|---|---|
| Operating Cash Flow | -$59.24M | -$57.31M | -$118.92M | -$372.98M | -$96.21M |
| Net cash flow from continuing operations | -$59.24M | -$57.31M | -$118.92M | -$372.98M | -$96.21M |
| Net Income from Continuing Operations | -$65.05M | -$100.70M | -$99.11M | -$412.78M | -$108.04M |
| Gain/Loss from Continuing Operations | $0.00 | -$67,000.00 | -$28,000.00 | -$113,000.00 | -$417,000.00 |
| Depreciation & Depletion & Amortization | $1.45M | $1.35M | $1.36M | $5.18M | $1.27M |
| Other Non-Cash Items | $3.39M | $28.32M | $3.26M | $22.43M | $3.20M |
| Change in Working Capital | -$14.78M | -$1.03M | -$38.80M | -$33.04M | -$4.59M |
| -Change in Receivables | -$8.68M | -$8.08M | -$5.56M | -$6.47M | -$5.55M |
| -Change in Inventory | -$7.69M | $4.94M | -$2.17M | -$5.30M | -$886,000.00 |
| -Change in Prepaid Assets | -$26,000.00 | -$4.89M | -$2.46M | -$3.17M | -$945,000.00 |
| -Change in Payables and Accrued Expense | $6.26M | $11.43M | -$24.16M | -$527,000.00 | $7.10M |
| -Change in Other Current Liabilities | -$4.64M | -$4.42M | -$4.46M | -$17.57M | -$4.31M |
| Net cash flow from investing | $83.96M | $40.21M | $141.31M | $377.18M | $90.08M |
| Net Cash Flow from Continuing Investing Activities | $83.96M | $40.21M | $141.31M | $377.18M | $90.08M |
| Net PPE Purchase and Sale | -$1.18M | -$1.21M | -$769,000.00 | -$4.32M | -$1.12M |
| Net Intangibles Purchase and Sale | $0.00 | – | – | -$10.00M | $0.00 |
| Net Investment Purchase and Sale | $85.14M | $66.42M | $142.08M | $391.50M | $91.20M |
| Financing Cash Flow | $4.18M | $3.15M | $2.08M | $8.68M | $2.56M |
| Net Cash Flow from Continuing Financing Activities | $4.18M | $3.15M | $2.08M | $8.68M | $2.56M |
| Proceeds from Stock Option Exercised | $4.18M | $3.15M | $2.08M | $8.68M | $2.56M |
| Ending Cash Balance | $128.55M | $99.65M | $113.60M | $89.13M | $89.13M |
| Net Change in Cash | $28.90M | -$13.95M | $24.47M | $12.88M | -$3.58M |
| Beginning Cash Balance | $99.65M | $113.60M | $89.13M | $76.25M | $92.71M |
| Free Cash Flow | -$60.42M | -$83.52M | -$119.69M | -$387.29M | -$97.33M |
| Net Business Purchase and Sale | – | – | – | $0.00 | $0.00 |
No comments yet — be the first to weigh in on AGIO.
Sign in to join the discussion.